Contents lists available at ScienceDirect

Prostaglandins and Other Lipid Mediators

Original research article

Hydrolysis of lipoproteins by sPLA₂'s enhances mitogenesis and eicosanoid release from vascular smooth muscle cells: Diverse activity of sPLA₂'s IIA, V and X

Pruzanski Waldemar^{a, c, *}, Julia Kopilov^a, Arnis Kuksis^{b, c}

^a St. Michael's Hopital, Toronto, Canada

^b The Banting and Best Department of Medical Research, Toronto, Canada

^c University of Toronto, Toronto, Canada

ARTICLE INFO

Article history: Received 2 June 2015 Received in revised form 1 December 2015 Accepted 8 December 2015 Available online 19 December 2015

Keywords: Eicosanoids Lipoproteins Mitogenesis Secretory phospholipases VSMC

ABSTRACT

Mitogenesis of Vascular Smooth Muscle Cells (VSMC) plays an important role in atherogenesis. Until recently, the effect of lipid subfractions has not been clarified. Secretory phospholipases A₂ (sPLA₂'s) hydrolyse glycerophospholipids and release pro-inflammatory lyso-lipids, oxidized and non-oxidized fatty acids and isoprostanes. They localize in the vascular wall. We hypothesized that structurally similar sPLA₂'s may exert different impact on VSMC. The influence of sPLA₂'s, IIA, V, X, HDL, LDL, and hydrolysis products was tested on mitogenesis of VSMC, i.e., the early effect on the cell membrane phospholipids, and on PGE₂ and LTB₄ release, i.e., late effect of Cyclooxygenase and 5-lipooxygenase activity in VSMC. Mitogenesis was significantly enhanced by HDL and LDL, and by products of sPLA₂ hydrolysis. Hydrolysis of HDL or LDL enhanced mitogenic activity in order V > X > IIA. The release of PGE₂ was enhanced by group X sPLA₂ and by HDL hydrolyzed by groups V and X. LDL and its hydrolysis products enhanced the release of PGE₂ in order X > V > IIA. The release of LTB₄ was markedly increased by LDL and HDL, and by hydrolytic products of group V and X, but not group IIA sPLA₂. Our study demonstrates a diverse interaction of pro-inflammatory sPLA₂'s with HDL and LDL affecting both mitogenesis and eicosanoid release from VSMC, therefore potentially enhancing their pro-atherogenic activity.

© 2015 Elsevier Inc. All rights reserved.

1. Introduction

Substantial progress has been made in the investigation of the pathogenic mechanisms of atherosclerosis (A-S) with emphasis on inflammatory [1–3] and immunological [4] factors, and on the interaction of cellular components in vascular wall with lipopro-

* Corresponding author at: Rosedale Medical Centre, 600 Sherbourne St. Suite 602, Toronto, Ontario M4X 1W4, Canada. Fax: +1 416972-0507.

E-mail address: drwpruzanski@bellnet.ca (W. Pruzanski).

http://dx.doi.org/10.1016/j.prostaglandins.2015.12.004 1098-8823/© 2015 Elsevier Inc. All rights reserved.

teins [5,6] and secretory phospholipases A₂ (sPLA₂) [7–9]. Vascular smooth muscle cells (VSMC) while quiescent under physiological conditions, are becoming proatherogenic when exposed to a variety of insults [10]. VSMC participate in the lipid overload and handling of modified LDL, cholesterol and other elements that play a major role in the development of atheromas [10]. Mitogenic activation followed by proliferation and migration of (VSMC) plays a major role in the development of atherosclerosis [10–12]. Previous work [13] has demonstrated the mitogenic effect of native plasma lipoproteins and the effects of their hydrolysis by group IIA sPLA₂. However, the effect of lipolysis products generated by the more extensive activity of group V and X sPLA₂s upon VSMC mitogenesis has not been previously reported. Unreported has also remained the effect of V and X sPLA₂ on biogenesis and extracellular release of PGE₂ and LTB₄ promoters of late stages of pro-inflammatory activity of VSMC [14].

Herein we report that native human lipoproteins, as well as $sPLA_2$'s, IIA, V, and X and especially $sPLA_2$ induced lipolytic products of HDL, HDL₃ and LDL induce mitogenic activity and extracellular





CrossMark

Abbreviations: ALDH, aldehyde dehydrogenase; COX-2, cyclooxygenase-2; DHA, docosahexaenoic acid; DNA, deoxyribonucleic acid; EPA, eicosapentaenoic acid; ESI, electrospray ionization; GroPCho, glycerophosphocholine; GSH, glutathione; HDL, high density lipoprotein; HNE, 4-hydroxy-*trans*-2-nonenal; IL-1 β , interleukin β ; LC/ESI-MSHNE, liquid chromatography/ESI-mass spectrometry; LDH, lactic dehydrogenase; LDL, low density lipoprotein; lysoPtdCho, lysophosphatidylcholine; LTB4, leukotriene B4; MAPK, mitogen activated protein kinase; NF- $\kappa\beta$, nuclear factor kappa-beta; PGE₂, prostaglandin E2; PGI₂, prostacyclin I2; PKC, protein kinase C; PtdCho, phosphatidylcholine; SUFA, polyunsaturated fatty acids; TBARS, thiobarbituric acid reactive substances; SPLA₂s, secretory human phospholipases A₂; VSMC, vascular smooth muscle cells.

release of PGE_2 and LTB_4 from human VSMC. Marked differences were detected in the impact of groups IIA, V and X sPLA₂'s.

2. Materials and methods

2.1. Cell culture

Human VSMC of male and female origin were cultured and maintained as described [13]. The source of VSMC and the methods for making VSMC quiescent and tested for morphology, size, shape, detachment and viability were previously reported in detail [13]. Before treatment with any agents, VSMC were made quiescent by culturing them for 48 h (with one medium change after 24 h) in serum-free medium containing FFA free 0.1% BSA, insulintransferrin-selenium supplement (ITS) (Gibco BRL., Burlington, Ontario, Canada), 0.1 mM vitamin C, 100 U/mL penicillin, 100 ug/mL streptomycin, and 0.25 ug/ml amphotericin B. In each experiment LDH release was also tested. Only viable, morphologically normal cells from passages 6 and 7 were used for the experiments.

2.2. Lipoproteins

Pure human HDL and LDL were purchased from Sigma–Aldrich (Toronto, ON, Canada) or received as a gift from Dr. F. C. De Beer. Purity and lack of oxidation were tested, as recorded [13]. The content of lioneic acid in HDL was $1.31 \,\mu$ mol/L and in LDL $5.5 \,\mu$ mol/L, while oleic acid made up 0.43 μ mol/L and $1.8 \,\mu$ mol/L, respectively. Only the lipid subfractions of highest purity, free from oxidized products as tested by chromatographic analysis were used. The content of linoleic acid in HDL was $1.31 \,\mu$ mol/L and $1.8 \,\mu$ mol/L, and in LDL $5.5 \,\mu$ mol/L, while oleic acid made up 0.43 μ mol/L and $1.8 \,\mu$ mol/L and $1.8 \,\mu$ mol/L, respectively. These concentrations were found to be non-toxic to the cells [14]. The molecular species composition of the glycerophospholipids has been described in detail elsewhere [15,16]. Linoleic, oleic and arachidonic acids and lysoPtdCho were purchased from Sigma–Aldrich, and tested by chromatography for purity and oxidation state in our laboratory.

2.3. Phospholipases

Recombinant human IIA sPLA₂ was provided by Dr. J. Browning, Biogen, Cambridge, MA, USA. Recombinant human group V sPLA₂ was prepared by Dr. Kwang Pyo Kim, University of Chicago, IL, US. Recombinant human group X sPLA₂ was prepared by Dr. G. Lambeau, Center National de la Recherche Scientifique, Sophia Antipolis, France.

2.4. Hydrolysis of lipoproteins

HDL and fresh non-oxidized LDL ($25-100 \mu g/mL$) were incubated for 1 to 24 h with sPLA₂'s (1.0-50 ng/mL) as described [13]. The products of enzyme hydrolysis as well as those of lipid peroxidation were identified by LC/ESI-MS as described [15,17].

2.5. Mitogenesis and cellular proliferation

[³H] Thymidine incorporation was measured as previously described [13] to determine the effect of exposure of human VSMC to sPLA₂'s, IIA, V and X, and to native and sPLA₂—digested lipoproteins. Each experiment was performed in triplicate, and repeated as described in the results.

2.6. PGE₂ and LTB₄ release

VSMC were grown to confluence as described [13], plated in 24-well plates, 6×104 cells per well in 1 mL of the medium for



\rightarrow Gr IIA sPLA₂ \rightarrow Gr V sPLA₂ \rightarrow Gr X sPLA₂

VSMC were incubated with sPLA₂ for 24 hrs.

* - p<0.01 **- p<0.001

Fig. 1. Mitogenic activity of VSMC induced by Gr IIA, V and X sPLA₂'s.

24 h and then made quiescent as reported [13]. VSMC were incubated with each lipoprotein alone, each sPLA₂ alone, or with each lipoprotein hydrolyzed by each sPLA₂ for various periods of time. In the incubations with VSMC, the lipoprotein hydrolysates were utilized together with the sPLA₂s used to produce them, as well as the albumin bound free fatty acids and lysophospholipids.

Leukotriene B₄ (LTB₄) was determined by enzyme immunoassay EIA system and Prostaglandin E₂ (PGE₂) by EIA system (Amersham Pharmacia Biotech, Canada). Optical density (450 nm) was measured on microtiter plate reader (Diagnostics Pasteur LP400). Concentrations of released LTB₄ and PGE₂ were measured in the supernatant. The results were normalized to 1×106 cells. The range of PGE₂ sensitivity was 0.84–100 ng/10⁶ cells and of LTB₄ 94–12000 pg/10⁶ cells.

Experiments were done in triplicate and repeated 3 or more times. The initial and final cell counts and microscopy were done and LDH concentration was tested in the medium by cytotoxicity Detection Kit (Roche Diagnostics, Mannheim, Germany). Microscopic assessment of the size and shape of cells and of their detachment was made.

2.7. Statistical analysis

Analysis of all experiments was performed by Student *t*-test, Tukey–Kramer multiple comparison test and Bartlett's test for homogeneity of variances.

3. Results

3.1. Exposure of VSMC to sPLA₂'s

Incubations of VSMC with sPLA₂'s ranged from 1 h to 24 h. Results of 24 h incubation at concentrations from 1 ng/mL to 50 ng/mL are shown in Fig. 1 and show concentration related increase in mitogenic activity (Fig. 1).

Exposure to sPLA₂ group IIA or to group X, up to the concentration of 50 ng/mL, did not significantly increase the mitogenic activity of VSMC, $(104 \pm 3\%)$ regardless of the duration of incubation. In contrast, exposure to sPLA₂ group V invariably resulted in dose related increase in mitogenic activity. VSMC exposed to

Download English Version:

https://daneshyari.com/en/article/2019504

Download Persian Version:

https://daneshyari.com/article/2019504

Daneshyari.com